A randomized, multicenter, phase 3 study of nivolumab vs sorafenib as first-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): CheckMate-459.

被引：28
|
作者：
Sangro, Bruno
Park, Joong-Won
Dela Cruz, Christine Marie
Anderson, Jeffrey
Lang, Lixin
Neely, Jaclyn
Shaw, James W.
Cheng, Ann-Lii
机构：
[1] Clin Univ Navarra & CIBERHD, Liver Unit, Pamplona, Spain
[2] Natl Canc Ctr, Ctr Liver Canc, Goyang, South Korea
[3] Bristol Myers Squibb, Princeton, NJ USA
[4] Natl Taiwan Univ, Coll Med, Grad Inst Oncol, Taipei, Taiwan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.TPS4147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS4147
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH Study
    Barone, C.
    Brandi, G.
    Daniele, B.
    Villa, E.
    Leo, S.
    Di Fabio, F.
    Aprile, G.
    Colombo, M.
    Sobrero, A.
    Giannelli, G.
    Porta, C.
    Cabibbo, G.
    Zhu, A.
    Blanc, J.
    Okusaka, T.
    Chau, I.
    Abada, P.
    Yang, L.
    Pastorelli, D.
    ANNALS OF ONCOLOGY, 2015, 26 : 91 - 91
  • [22] A Multicenter Phase II Study of Second-Line Axitinib for Patients with Advanced Hepatocellular Carcinoma Failing First-Line Sorafenib Monotherapy
    Lin, Zhong-Zhe
    Chen, Bang-Bin
    Hung, Yi-Ping
    Huang, Po-Hsiang
    Shen, Ying-Chun
    Shao, Yu-Yun
    Hsu, Chih-Hung
    Cheng, Ann-Lii
    Lee, Rheun-Chuan
    Chao, Yee
    Hsu, Chiun
    ONCOLOGIST, 2020, 25 (09): : E1280 - E1285
  • [23] A randomized phase II open label multi-institution study of the combination of bevacizumab (B) and erlotinib (E) compared to sorafenib (S) in the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC).
    Thomas, Melanie B.
    Garrett-Mayer, Elizabeth
    Anis, Munazza
    Anderton, Kate Robertson
    Bentz, Tricia A.
    Adelman, Andie Ray
    Brisendine, Alan
    Duddalwar, Vinay
    Weiss, Geoffrey R.
    Siegel, Abby B.
    Bendell, Johanna C.
    Baron, Ari David
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [24] Nivolumab in sorafenib-experienced patients with advanced hepatocellular carcinoma (HCC) with or without chronic viral hepatitis: CheckMate 040 study
    Sangro, B.
    Yau, T.
    Hsu, C.
    Kudo, M.
    Crocenzi, T. S.
    Choo, S. -P.
    Meyer, T.
    Welling, T. H., III
    Yeo, W.
    Chopra, A.
    Baakili, A.
    Dela Cruz, C.
    Lang, L.
    Neely, J.
    Melero, I.
    El-Khoueiry, A. B.
    Trojan, J.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S34 - S35
  • [25] Economic burden of advanced hepatocellular carcinoma (HCC) in Spain among patients discontinuing first-line sorafenib
    Liepa, Astra M.
    Candrilli, Sean D.
    D'yachkova, Yulia
    Taipale, Kaisa
    Kaye, James A.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [26] Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
    Llovet, Josep M.
    Kudo, Masatoshi
    Cheng, Ann-Lii
    Finn, Richard S.
    Galle, Peter R.
    Kaneko, Shuichi
    Meyer, Tim
    Qin, Shukui
    Dutcus, Corina E.
    Chen, Erluo
    Dubrovsky, Leonid
    Zhu, Andrew X.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [27] PHARMACOECONOMIC EVALUATION OF SORAFENIB AS FIRST-LINE TREATMENT FOR ADVANCED HEPATOCELLULAR CARCINOMA
    Naumovska, Z.
    Nestorovska, Kapedanovska A.
    Grozdanova, A.
    Suturkova, L.
    Dimovski, A.
    Sterjev, Z.
    VALUE IN HEALTH, 2017, 20 (09) : A736 - A736
  • [28] Analysis of serum biomarkers (BM) in patients (pts) from a phase 3 study of lenvatinib (LEN) vs sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC)
    Finn, R. S.
    Kudo, M.
    Cheng, A-L.
    Wyrwicz, L.
    Ngan, R.
    Blanc, J-F.
    Baron, A. D.
    Vogel, A.
    Ikeda, M.
    Piscaglia, F.
    Han, K-H.
    Qin, S.
    Minoshima, Y.
    Funahashi, Y.
    Ren, M.
    Dairiki, R.
    Sachdev, P.
    Tamai, T.
    Dutcus, C.
    Evans, T. R. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [29] Lenvatinib combined with transarterial chemoembolization as first-line treatment of advanced hepatocellular carcinoma: A phase 3, multicenter, randomized controlled trial
    Peng, Zhenwei
    Fan, Wenzhe
    Zhu, Bowen
    Li, Jiaping
    Kuang, Ming
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [30] Phase Ib/II study of sorafenib (SOR) and pembrolizumab (PEM) in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Iyer, Renuka
    Sonti, Sahithi
    Mahalingam, Devalingam
    Mukherjee, Sarbajit
    Chakraborty, Sayan
    Attwood, Kristopher
    George, Anthony
    Maguire, Orla
    Minderman, Hans
    Fountzilas, Christos
    CANCER RESEARCH, 2024, 84 (07)
12345